NICE backs Pfizer's Bosulif in first reappraisal of cancer fund drug

The U.K.'s NICE issued a final appraisal determination recommending use of leukemia drug Bosulif bosutinib from Pfizer Inc. (NYSE:PFE). The recommendation is the first reappraisal of a drug that was covered by the U.K.'s Cancer Drugs Fund since NICE integrated the fund into its appraisal process.

NICE issued a FAD recommending against Bosulif in 2013, and the dual inhibitor of BCR-ABL and Src kinase subsequently was made available by the CDF. NICE began reassessing drugs covered in the fund in April. ...